REGENXBIO (RGNX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.43
- Estimate
- -$0.11
- Surprise
- +499.2%
- Revenue (period 2026-06-30)
- $108.0M
- Score today
- 5.2/10
Revenue source: xbrl.
How the report landed
REGENXBIO (RGNX) beat the -$0.11 estimate with diluted EPS of $0.43 — a large 499.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates RGNX Sell at 5.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +499.2% surprise compares with a +107.6% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: lead product candidates
- Quality below floor (3.9 < 4.0)
- Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.18
- Price target
- $20.64
- Stop
- $8.55
- Upside to target
- +124.8%
- Reward-to-risk
- 8.3:1
Model outputs from TrendMatrix’s engine as of 2026-09-03 — shown for context, not personalized investment advice.
RGNX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $633.7M
- P/E (fwd)
- -3.2
- 52-week range
- $5.46–$16.19
- Off 52-week high
- 43.3%
- RSI (14)
- 41
- Volume vs avg
- 0.13×
- Score today
- 5.2/10